Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of “Buy” by Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $13.00.

A number of brokerages recently issued reports on HUMA. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Thursday, November 21st. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Humacyte in a report on Wednesday, November 13th.

Insider Buying and Selling at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

Hedge funds have recently modified their holdings of the business. Endowment Wealth Management Inc. lifted its position in Humacyte by 3.1% during the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after buying an additional 3,000 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Humacyte in the 2nd quarter worth $28,000. Private Advisor Group LLC raised its holdings in shares of Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after acquiring an additional 6,510 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Humacyte by 32.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after acquiring an additional 8,557 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after acquiring an additional 8,965 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Trading Down 6.8 %

Shares of HUMA opened at $3.54 on Thursday. The firm has a market cap of $445.54 million, a P/E ratio of -2.64 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte has a 1 year low of $2.48 and a 1 year high of $9.97. The company has a 50 day simple moving average of $4.89 and a two-hundred day simple moving average of $5.88.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.